• By ICR Secretariat
  • Posted Friday, July 8, 2022

Novartis, staring down tough market for M&A, leans toward $25B Sandoz spinoff: Bloomberg

https://www.fiercepharma.com/pharma/novartis-starting-down-tough-market-ma-mulls-sandoz-spinoff-bloomberg

For months, the industry has waited patiently as Novartis mulls the fate of its $25 billion generics arm. Now, it appears a spinoff could be in the cards.